Thermo Fisher Scientific's Robust Dividend Amid Market Fluctuations

Reported 2 days ago

Thermo Fisher Scientific Inc. (TMO), recognized as one of the top pharma dividend stocks to buy in 2025, has faced a stock decline of over 21% this year. Despite this, the company remains strong in long-term growth due to its diverse operations and high-margin recurring revenues, which account for 83% of its sales. In Q1 2025, it reported a slight revenue increase to $10.36 billion, exceeding analyst expectations. With a solid cash position and an increase in its dividend for eight consecutive years to $0.43 per share, TMO is highlighted as a reliable dividend payer, although some investors may find more appealing opportunities in AI stocks.

Source: YAHOO

View details

You may also interested in these wikis

Back to all Wikis